Perhaps most importantly, our studies reveal that even low concentrations of endoxifen, mimicking that of poor and intermediate CYP2D6 metabolizers, results in repression of estrogen induced breast cancer proliferation in cells expressing ERβ, but not in those that express only ERα. Here, ESR2 is linked to breast cancer.